Rabies is a rare but invariably fatal viral infection of the central nervous system caused by Lyssavirus, a member of the Rhabdoviridae family. It is classified as a zoonosis, meaning it is transmitted from animals to humans. Although rabies affects fewer than 1 in 1,000,000 people in developed countries, it remains a significant public health concern globally. Without timely intervention, the disease progresses to fatal encephalopathy. This summary reflects clinical data available as of 2026-05-10.

Rabies infection progresses through several stages. An initial prodromal phase may include non-specific symptoms such as fever, headache, and malaise, sometimes accompanied by pain or tingling at the site of the animal bite. As the virus travels to the central nervous system, neurological symptoms develop. These may include agitation, confusion, hallucinations, excessive salivation, and difficulty swallowing — sometimes manifesting as an aversion to water (hydrophobia) or air (aerophobia). In advanced disease, patients may experience paralysis, loss of consciousness, and coma. Not all individuals experience all features, and severity varies considerably.

Rabies is caused by infection with Lyssavirus, most commonly transmitted through the saliva of an infected animal via a bite wound. Common animal reservoirs include bats, dogs, raccoons, foxes, and other mammals. Rabies is not a genetic or inherited condition; it is acquired through exposure to an infected animal. The virus travels along peripheral nerves to the brain, causing widespread neuroinflammation. Person-to-person transmission has not been documented through ordinary contact, though rare cases through organ transplantation have been reported.

Diagnosis of rabies can be difficult before the onset of symptoms because no reliable test exists to confirm infection in the pre-symptomatic period. Once neurological symptoms appear, laboratory testing on saliva, cerebrospinal fluid, serum, or skin biopsy samples can detect the virus or antibodies. The direct fluorescent antibody test on brain tissue is considered the gold standard but requires post-mortem examination in many cases. A high clinical index of suspicion following a potential animal exposure is critical for initiating timely post-exposure prophylaxis.

Post-exposure prophylaxis (PEP) is the cornerstone of rabies prevention and is highly effective when administered promptly after a suspected exposure. PEP consists of thorough wound cleaning, administration of rabies immune globulin, and a course of rabies vaccine. Pre-exposure prophylaxis with rabies vaccine is recommended for individuals at high occupational risk, such as veterinarians and animal handlers. Once clinical disease has developed, no proven curative therapy exists, and rabies remains almost universally fatal. Supportive intensive care may be provided. Several experimental approaches are under investigation in clinical trials.

Without post-exposure prophylaxis following an exposure, and once clinical signs of rabies encephalopathy develop, the prognosis is extremely poor. Survival without PEP after symptom onset is exceedingly rare. With prompt and complete post-exposure prophylaxis following a known exposure, infection can be reliably prevented. Early wound care and timely initiation of immunization are the most critical factors determining outcome.

Active research in rabies focuses on improving vaccine formulations and delivery strategies, with multiple Phase 2 and Phase 3 clinical trials evaluating novel vaccine candidates and dosing regimens. Investigators are also studying anti-rabies virus monoclonal antibodies as adjuncts to existing post-exposure prophylaxis protocols. Published research includes epidemiological studies, case reports, and clinical trial publications examining immunogenicity and safety. Rabies remains a disease where global prevention efforts, animal vaccination programs, and access to post-exposure treatment are central to reducing mortality.